Neuroscience Focus Areas:
Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for UK Healthcare Professionals only

      Contact us

      Please complete the form below and a member of the BOTOX® (botulinum toxin type A) team will get back to you.

      Please fill in your details below only if you are a UK registered healthcare professional and would like to be contacted by an AbbVie representative.

      BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).1

      The BOTOX® (botulinum toxin type A) prescribing information and adverse event reporting information can be found at the bottom of the page.

      Please enter First name
      Please enter Last name
      Please enter Role
      E-mail address is not valid
      Please enter Last name
      Please enter Hospital name
      Please enter hospital postcode

      Please select the items you are interested in:

      Please select one field.

      Please note that there may be certain circumstances where we contact you in relation to important AbbVie product or information which we are required to provide to you or your patients as a matter of law, or in order to comply with the obligations we owe to you or them. This type of communications does not constitute as promotional communication.

      You can withdraw your consent at any time by using the unsubscribe option in the email or contacting [email protected]. For further information about AbbVie’s privacy practices, please refer to the AbbVie Privacy notice.

      Please select one field.


      Please refer to the AbbVie privacy notice here for more information on how AbbVie processes your personal data and your data privacy rights.

      *Denotes mandatory field

      Incorrect. Please try again.

       

      References

      1. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk. Accessed August 2023

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

      BOTOX® PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.

      Adverse events should also be reported to AbbVie on [email protected]

      Date of preparation: August 2023. UK-BCM-230141.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on [email protected]

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.